On September 7, 2021 Bioneer reported that it is delighted to participate to the 23rd Symposium "Signal Transduction at the Blood-Brain Barriers", held September 22-24, 2021, as a virtual symposium (Press release, Bioneer, SEP 7, 2021, View Source;utm_medium=rss&utm_campaign=signal-transduction-at-the-blood-brain-barriers-virtual-symposium-september-22-24-2021 [SID1234587303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 23rd International Symposium "Signal Transduction at the Blood-Brain Barriers" was originally planned for September 2021 in Bari / Italy, but had to be postponed to September/October 2022. The Scientific Board of the symposium decided to organize the: 23rd Symposium "Signal Transduction at the Blood-Brain Barriers", held September 22-24, 2021, as a virtual symposium.

Dr. Lasse Saaby, Head of Operations at Bioneer:FARMA, will be participating with a 20 min presentation on the elucidation of a possible digoxin-binding site in the substrate-binding pocket of P-glycoprotein. The presentation will be held on September 23rd at 15:25.

In this talk, Lasse will present the efforts to explore the possible existence of a digoxin-binding site different from the putative H- and R-binding sites previously described for P-gp will be presented. This will cover the use of a polarized confluent cell monolayer model over-expressing human P-gp to study interactions between digoxin and known P-gp substrates and inhibitors.

Scientists interested in signaling processes at the neurovascular unit are invited to join the Virtual Symposium "Signal Transduction in the Blood-Brain Barriers". The symposium will be organized in the tradition of the previous meetings of this series, with online lectures and poster presentations, both expected to present new and exciting data.

The symposium is supported by the International Brain Barriers Society (IBBS).

On September 7, 2021 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President will present at the Morgan Stanley 19th Annual Healthcare Conference on September 14, 2021 at 4:15 PM ET (Press release, Ultragenyx Pharmaceutical, SEP 7, 2021, View Source [SID1234587302]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On September 7, 2021 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System, reported that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, to be held virtually September 13-15, 2021 (Press release, iBioPharma, SEP 7, 2021, View Source [SID1234587301]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

iBio’s pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, September 13, 2021, the presentation will also be available on the Company’s website at www.ibioinc.com under "News & Events" in the Investors section.

On September 7, 2021 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that Laurent Levy, Chief Executive Officer, will present the Company’s latest corporate and clinical developments during a webcast at the virtual H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Nanobiotix, SEP 7, 2021, View Source [SID1234587299]). The presentation will be available on-demand starting at 7:00 AM EDT / 1:00 PM CET on Monday, September 13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the event will be available for 90 days on the events section of the Company’s website.

On September 7, 2021 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, taking place September 13 – 15, 2021 (Press release, Aileron Therapeutics, SEP 7, 2021, View Source [SID1234587298]). Dr. Aivado’s presentation will include an update on the company’s progress advancing ALRN-6924 as a selective chemoprotective agent for patients with p53-mutated cancers regardless of type of cancer or chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An on-demand corporate presentation will be accessible to registered conference attendees starting on Monday, September 13, 2021 at 7 am ET. A recorded webcast of the presentation will be archived under the Investors and Media section of Aileron’s website at View Source for 30 days following the event. Aileron management will conduct one-on-one meetings with investors during the conference.